Investigating MMP9 polymorphism as a risk factor in thyroid cancer

Introduction: Papillary thyroid carcinoma (PTC) is the most common malignancy of the thyroid, with a rapid global rise in incidence in the recent decades. Matrix metalloproteinase-9 (MMP-9) is proved to play important role in tumor progression and the metastatic process in the majority thyroid cancers. MMP-9 belongs to a family of zinc-dependent neutral endopeptidases capable of degrading all matrix components. In the present study we evaluated the presence of MMP-9 (rs17576) polymorphism in the microRNA gene of thyroid cancer patients. Material and Methods: Tetra-ARMS polymerase chain reaction (PCR) was used to assess the MMP-9 rs17576 level in the peripheral blood of 210 patients with thyroid carcinoma and 210 healthy volunteers from Namazi Hospital of Shiraz.Results: The frequency of MMP9-AG (OR=1.148, 95%CI=0.755-1.745, P =0.520) and MMP9-GG (OR=0.727, 95%CI=0.409-1.292, P =0.277) did not show a significant difference between the patient and control groups. Conclusion: Although there was no significant difference in MMP9 rs17576 polymorphism between the two groups, the risk of thyroid cancer in MMP9-AG genotype is 1.1 folds higher than healthy individuals. While, MMP9-GG genotype showed a 0.727 lower risk of getting thyroid cancer. The MMP9 rs17576 can be considered as a risk factor for thyroid cancer.

کلیدواژه ها:

MMP9 ، polymorphism ، Thyroid cancer